December 15, 2025 · Phase 2 readout
LTRN Phase 2 readout: a negative outcome, -6.4%
On December 15, 2025, LP-300 — Lantern Pharma Inc. (Adenocarcinoma of Lung) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -6.4% in the window around the event. It had already run +6.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$3.60
1d before
$3.37
Event day
$3.33
1d after
$3.26
5d after
Pre-catalyst setup
+6.5%
30-day run-up
8503%
30-day volatility
0.4×
volume spike